{"title":"AGEX: a comprehensive database of clinically relevant genetic variants associated with Alagille syndrome across diverse populations.","authors":"Priya Sharma, Vishnu Prasad, Bhanu Teja Korra, Rohan Grotra, Rohan Malik, Rahul Kumar, Deepti Abbey","doi":"10.1007/s12072-026-11074-8","DOIUrl":"10.1007/s12072-026-11074-8","url":null,"abstract":"<p><strong>Background: </strong>Alagille syndrome (ALGS) is a rare multisystem disorder primarily caused by pathogenic variants in JAG1 and NOTCH2. Although its genetic basis is well established, existing variant repositories often lack comprehensive clinical annotation, sufficient ethnic representation, and open accessibility. These limitations reduce their translational relevance and hinder genotype-phenotype correlation and evidence-based molecular diagnosis. To address this gap, we developed AGEX (Alagille Genetics Exploration Database), a curated, open-access resource integrating genetic variants with phenotype and population frequency data.</p><p><strong>Methods: </strong>AGEX ( http://agexbase.iitd.ac.in ) was constructed through a systematic literature review from 1999-2025, supplemented with unpublished case reports from Indian ALGS patients. Variants were curated and classified according to ACMG/AMP guidelines, with pathogenicity predictions derived from multiple in silico tools. Population allele frequency data were integrated from gnomAD, All of Us, and IndiGenome databases. Domain-level mutation mapping was performed to assess variant distribution across functional protein regions. Additionally, a prototype ALGS Severity Tier Calculator was developed to integrate genotype and phenotype parameters for semi-quantitative clinical stratification.</p><p><strong>Results: </strong>AGEX compiles 260 variants, including 231 in JAG1 and 29 in NOTCH2, reported across 20 global populations. Four previously unreported variants were identified. Domain-level analysis revealed recurrent clustering of mutations within the DSL and EGF-like domains of JAG1, emphasizing their importance in Notch signaling. The database provides an interactive interface enabling variant browsing, phenotype-linked queries, and population-level analyses, along with a prototype severity scoring framework.</p><p><strong>Conclusion: </strong>AGEX represents the first dedicated integrative database for ALGS, enabling variant browsing, population-specific analyses, and phenotype-linked searches. While further longitudinal clinical validation is required, AGEX represents the first dedicated, integrative database for ALGS. By centralizing variant and clinical data, AGEX aims to accelerate diagnosis, improve patient stratification, and facilitate precision medicine strategies targeting Notch pathway dysregulation, serving as a scalable model for other rare disorder genomics.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1409-1419"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neutrophil extracellular traps drive cholangiocyte injury via ZNF709-TP53-MDM2 pathway in primary biliary cholangitis.","authors":"Mingxin Su, Zhenfeng Tian, Miao Yu, Enlai Huang, Jinjian Liang, Bingrong Hu, Yinting Chen","doi":"10.1007/s12072-026-11128-x","DOIUrl":"10.1007/s12072-026-11128-x","url":null,"abstract":"<p><strong>Background: </strong>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease in which many patients respond inadequately to ursodeoxycholic acid (UDCA) and may progress to liver failure. Although research on PBC has primarily centered on lymphocyte-mediated mechanisms, increasing evidence implicates neutrophils in autoimmunity, yet their role in PBC remains unclear.</p><p><strong>Methods: </strong>Cytokine screening of patient sera collected from our medical center was performed to identify NETs-inducing factors. Transcriptomic profiling was conducted to determine the molecular effects of NETs on cholangiocytes. The therapeutic effects of the neutrophil elastase inhibitor sivelestat on NETs-associated injury were evaluated in dnTGFβRII and 2OA-BSA murine models of PBC.</p><p><strong>Results: </strong>We identify NETs as a critical mediator linking immune activation to biliary injury. NETs formation was markedly elevated in PBC patient samples and murine models. Exploratory cytokine profiling of patient serum samples prioritized resistin as a leading candidate mediator of NETs formation, and elevated circulating resistin levels were confirmed in an independent clinical cohort. Further analysis of patient clinical data revealed that circulating resistin levels were positively correlated with cholestasis. Transcriptomic profiling demonstrated that NETs exposure downregulated ZNF709 and activated the TP53-MDM2 pathway in cholangiocytes, leading to epithelial injury and PBC-like phenotypic changes. In vivo, treatment with sivelestat significantly reduced biliary inflammation and fibrosis, while combination therapy with UDCA produced synergistically therapeutic benefits.</p><p><strong>Conclusions: </strong>These findings identify a resistin-NETs-ZNF709 axis that links neutrophil activation to cholangiocyte injury in PBC and suggest that targeting NETs-associated injury with sivelestat may represent a potential strategy to improve current PBC therapies.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1446-1462"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HBV RNA, HBcrAg, and HBsAg levels at year 6 do not predict HCC risk in patients with cirrhosis on long-term entecavir therapy.","authors":"Hung-Hsuan Pan, Tung-Hung Su, Tsung-Hui Hu, Wan-Long Chuang, Wei-Wen Su, Chun-Che Lin, Cheng-Yuan Peng, Chia-Chi Wang, Yao-Chun Hsu, Yi-Wen Huang, Kuo-Chih Tseng, Chih-Lin Lin, Sheng-Shun Yang, Fat-Moon Suk, Shih-Jer Hsu, Tsung-Ming Chen, Ming-Jong Bair, Cheng-Kuan Lin, Tai-Chung Tseng, Jia-Horng Kao","doi":"10.1007/s12072-026-11137-w","DOIUrl":"10.1007/s12072-026-11137-w","url":null,"abstract":"<p><strong>Background and aims: </strong>The prognostic value of on-treatment hepatitis B virus (HBV) RNA, hepatitis B core-related antigen (HBcrAg), and quantitative hepatitis B surface antigen (HBsAg) for hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) remains uncertain. We evaluate the predictive roles of these viral markers in patients with CHB receiving long-term entecavir therapy.</p><p><strong>Methods: </strong>This prospective, multicenter study enrolled patients with CHB-related cirrhosis undergoing long-term entecavir treatment and HCC surveillance in Taiwan. Serum HBV RNA, HBcrAg, and HBsAg levels were measured at enrollment. Multivariable regression identified predictors of HBV RNA positivity and HCC development.</p><p><strong>Results: </strong>Overall, 451 patients were included. After a median of 6.2 years of antiviral therapy, the median levels of HBV RNA, HBcrAg, and HBsAg were 0.9 log10 copies/mL, 3.2 log10 U/mL, and 2.4 log10 IU/mL, respectively. During a median 3.3-year follow-up, 55 developed HCC. 57.2% of patients had detectable HBV RNA. HBV RNA detectability was associated with older age, lower alanine aminotransferase (ALT), HBeAg positivity, and higher HBsAg and HBcrAg levels. In multivariable analysis, higher fibrosis-4 (FIB-4) index (adjusted subdistribution hazard ratio [aSHR], 1.10; 95% confidence interval [CI] 1.00-1.21) and elevated alpha-fetoprotein (AFP) (aSHR, 1.01; 95% CI 1.00-1.01) independently predicted HCC development, whereas the three viral markers did not.</p><p><strong>Conclusion: </strong>After a 6-year entecavir therapy, 57.2% of patients with CHB-related cirrhosis had detectable HBV RNA. Year-6 HBV RNA, HBcrAg, and HBsAg levels were not predictive of HCC, while FIB-4 index and AFP remained independent predictors.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1329-1339"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2025-10-29DOI: 10.1007/s12072-025-10947-8
Zhexian Liu, Na Li
{"title":"Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions.","authors":"Zhexian Liu, Na Li","doi":"10.1007/s12072-025-10947-8","DOIUrl":"10.1007/s12072-025-10947-8","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1499-1500"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-08-04DOI: 10.1007/s12072-026-11134-z
Jared L Delahaye, Shihyun You, Kai Fu, Scott Van Buren, Cheng Zhu, William Jordan, Avijit Ray, Johannes M Freudenberg, Kristen M Consalvo, Luca Pagliaroli, Sohil Joshi, Puneet Dhawan, Dickens Theodore, Melanie Paff, Jill Walker, Jennifer M Singh
{"title":"Bepirovirsen induces innate immune proteins independent of HBV.","authors":"Jared L Delahaye, Shihyun You, Kai Fu, Scott Van Buren, Cheng Zhu, William Jordan, Avijit Ray, Johannes M Freudenberg, Kristen M Consalvo, Luca Pagliaroli, Sohil Joshi, Puneet Dhawan, Dickens Theodore, Melanie Paff, Jill Walker, Jennifer M Singh","doi":"10.1007/s12072-026-11134-z","DOIUrl":"10.1007/s12072-026-11134-z","url":null,"abstract":"<p><strong>Background: </strong>Bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus (HBV) mRNAs, is in development for the treatment of chronic HBV infection. Clinical studies have demonstrated that bepirovirsen has multiple mechanisms of action, including lowering HBV DNA, reducing viral protein production, and inducing immune activation. Post hoc analysis of biomarker samples from three studies was performed to further characterize changes in soluble protein biomarkers after bepirovirsen dosing.</p><p><strong>Methods: </strong>Across three studies (CS3 [NCT02981602] in participants with chronic HBV infection; PFS [NCT06058390] and QTc [NCT06422767] in healthy volunteers) participants received bepirovirsen (150 mg, 300 mg, or 450 mg) or placebo. Longitudinal serum samples were taken for exploratory proteomics analysis. Relative expression of soluble proteins, including immune-related biomarkers, was measured, and differential expression was determined across arms. Clustering analysis was performed to identify kinetic patterns.</p><p><strong>Results: </strong>Bepirovirsen induced significant, transient protein differential expression in the hours after dosing, while there were relatively minor changes in placebo. There were many similarities in protein biomarkers induced in CS3 participants with chronic HBV infection and in the two healthy volunteer studies. Additionally, bepirovirsen treatment increased abundance of many proteins to a higher degree with increasing dose.</p><p><strong>Conclusions: </strong>These findings strengthen the association between bepirovirsen treatment and changes in innate immune-related proteins and indicate that this effect does not require the presence of HBV. The kinetic patterns of protein expression suggest that there are multiple waves of protein induction, which could impact recruitment and activation of innate and adaptive immune cell types.</p><p><strong>Clinical trial number: </strong>NCT02981602, NCT06058390, NCT06422767.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1318-1328"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-06-03DOI: 10.1007/s12072-026-11099-z
Ye Zhu, Kexin Wu, Tianyu Wu, Da Fang, Pengzi Zhang, Jin Wang, Yan Bi
{"title":"Prolactin acts on proopiomelanocortin neurons to regulate hepatic lipid metabolism.","authors":"Ye Zhu, Kexin Wu, Tianyu Wu, Da Fang, Pengzi Zhang, Jin Wang, Yan Bi","doi":"10.1007/s12072-026-11099-z","DOIUrl":"10.1007/s12072-026-11099-z","url":null,"abstract":"<p><strong>Objective: </strong>To elucidate the central mechanism of pituitary-derived prolactin (PRL) in hepatic lipid homeostasis and identify therapeutic targets for metabolic dysfunction-associated fatty liver disease (MASLD).</p><p><strong>Methods: </strong>High-fat diet (HFD)-fed mice induced MASLD. PRL⁻/⁻ mice, POMC neuron-specific PRL receptor (PRLR) conditional knockout mice, AAV-mediated PRLR knockdown, and central/peripheral PRL administration were used to explore PRL's central regulatory role. Metabolic phenotyping, histological/biochemical assays, immunofluorescence, electrophysiology, RNA-seq, 6-OHDA-induced sympathetic denervation, and primary hepatocyte experiments were performed to evaluate phenotypes, neuronal activity and underlying mechanisms.</p><p><strong>Results: </strong>PRL deficiency exacerbated HFD-induced hepatic lipid deposition, and central intracerebroventricular PRL alleviated hepatic steatosis in HFD-fed PRL⁻/⁻ and wild-type mice more rapidly than peripheral intraperitoneal PRL. PRLR was highly expressed in hypothalamic arcuate nucleus POMC neurons, which PRL selectively activated by enhancing neuronal excitability. POMC-specific PRLR knockout abrogated PRL's anti-steatotic effects and aggravated HFD-induced hepatic lipid accumulation. Mechanistically, central PRL enhanced hepatic sympathetic outflow to suppress de novo lipogenesis via the FASN pathway.</p><p><strong>Conclusion: </strong>PRL acts on hypothalamic POMC neurons to enhance hepatic sympathetic activity, suppressing FASN-mediated lipogenesis and maintaining lipid homeostasis. This novel PRL-driven brain-liver circuit highlights central PRL signaling as a promising MASLD therapeutic target.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1395-1408"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-06-29DOI: 10.1007/s12072-026-11118-z
Yannan Zhang, Zheng Li, Jinyu Sun, Changhao Xu, Min Gao, Hui Shen, Dongxu Hua, Qiyang Xie, Yi Xiao, Yuanjie Huang, Peng Li, Wei Sun, Xiangqing Kong
{"title":"Pathological transcriptional retention of Cyp26b1 in perirenal adipose-derived stem cells contributes to MASLD progression.","authors":"Yannan Zhang, Zheng Li, Jinyu Sun, Changhao Xu, Min Gao, Hui Shen, Dongxu Hua, Qiyang Xie, Yi Xiao, Yuanjie Huang, Peng Li, Wei Sun, Xiangqing Kong","doi":"10.1007/s12072-026-11118-z","DOIUrl":"10.1007/s12072-026-11118-z","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent liver disorder linked to metabolic syndrome, but its extrahepatic drivers and persistence mechanisms remain unclear.</p><p><strong>Methods: </strong>Transcriptomics was performed on adipose-derived stem cells (ADSCs) from distinct adipose depots in dynamic MASLD mouse models. A dietary reversal model was used to assess transcriptional retention. Candidate genes were identified via integrated DNA methylome and transcriptome analysis. Cyp26b1 function was tested by perirenal ADSCs-specific knockdown, and involved downstream mechanisms were investigated.</p><p><strong>Results: </strong>Perirenal ADSCs exhibited an early dysregulated transcriptional signature in MASLD and retained high transcriptional retention after reversal. Multi-omics identified Cyp26b1 as a persistent, epigenetically regulated driver. Knockdown of Cyp26b1 in perirenal ADSCs attenuated MASLD progression, potentially by modulating the CCL3-CCR5 axis to alleviate hepatic steatosis and inflammation.</p><p><strong>Conclusion: </strong>This study reveals an ADSC-mediated perirenal adipose-liver axis and establishes pathological \"memory\" in ADSCs as a perpetuating factor in MASLD. Transcriptional retention in perirenal ADSCs and its key regulator Cyp26b1 represent potential theoretical targets for exploring the mechanism and intervention of cellular \"memory\" in MASLD.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1353-1371"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-02DOI: 10.1007/s12072-026-11040-4
Xuping Zhang, Qian Li, Peipei Zhang
{"title":"Refining the definition of acute autoimmune hepatitis: implications for classification and prognosis.","authors":"Xuping Zhang, Qian Li, Peipei Zhang","doi":"10.1007/s12072-026-11040-4","DOIUrl":"10.1007/s12072-026-11040-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1533-1534"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-04DOI: 10.1007/s12072-026-11046-y
Young Mi Jung, Geum Joon Cho, Won Kim
{"title":"Response to Letter to Editor: Revisiting MASLD-based pregnancy risk stratification.","authors":"Young Mi Jung, Geum Joon Cho, Won Kim","doi":"10.1007/s12072-026-11046-y","DOIUrl":"10.1007/s12072-026-11046-y","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1528-1529"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}